SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weaker-than-expected fourth-quarter outlook, alongside slowing PC demand and supply constraints, overshadowed stronger quarterly results and drove a sharp selloff. Traders are split between expecting further losses and viewing the drop as an overreaction and a dip-buying opportunity.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and outlook triggered a selloff as investors focused on heavy AI and data-center spending, weaker cash flow, and modest misses against expectations, despite accelerating AWS growth. Traders are split between viewing the spending as a threat to returns and seeing AWS demand as justification for the investment.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 AML trial reached its prespecified 80th death event, triggering final analysis ahead of the awaited overall-survival readout. Bulls interpret the prolonged trial as encouraging and speculate about a buyout or short squeeze, while skeptics stress that the event milestone does not establish efficacy and note the share-price decline after it was announced.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits shares are under pressure after a strong quarterly report was overshadowed by a softer revenue outlook, declining Google search referrals and weakness in U.S. daily users. Traders are especially divided over the planned logged-in-only access test: critics fear it will reduce traffic, while some bulls see the selloff as an overreaction to a still-growing business.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Updated Lifileucel results in a lung-cancer trial triggered a sharp selloff, with traders focused on the 24.6% response rate across the broader patient group versus 59.1% in a retrospectively identified biomarker subgroup. The community is split between viewing the subgroup as a promising precision-treatment path and worrying that immature durability data, regulatory uncertainty, and a confusing presentation weaken the broader approval case.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks strong quarterly results, higher outlook and announced stock split are drawing attention, but shares fell alongside a broader tech and semiconductor selloff after a sharp rally. Traders are split between viewing the drop as an overreaction to solid demand and fundamentals and seeing it as profit-taking or a sign of cooling AI momentum and elevated expectations.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows quarterly report sparked a sharp selloff as investors focused on a softer contracted-revenue growth outlook and a slight earnings miss, despite continued revenue growth and raised AI targets. Traders are split between seeing the drop as an overreaction and buying opportunity and viewing it as a reset of lofty growth and AI expectations.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

A suspected major Binance security breach is dominating discussion, with traders citing reports of large crypto losses and suspended deposits and withdrawals as reasons for concern about exchange security and broader crypto-market weakness. Some community members question the reports or call them market FUD, while others fear a repeat of past exchange failures.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is drawing attention amid a cybersecurity-sector selloff following Fortinets weak service-revenue outlook, with traders describing PANWs decline as sympathy selling rather than a company-specific report. Some see the pullback as a buying opportunity, while others point to rich sector valuations and question whether growth can justify them.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubriks strong quarterly results and raised full-year outlook have been met with a sharp sell-the-news reaction, as traders focus on slower cloud net-new ARR growth and cautious second-half guidance after a strong run-up. Bulls see durable demand and improving cash generation, while bears question the outlook, valuation, and managements guidance credibility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TLX Stock Clocks 5% Gain This Week Ahead Of FDA Decision On Brain Cancer Imaging Agent 

Equity

The FDA’s target date for deciding on Pixclara is September 11.

CRTO Stock Clocks Best Day In Nearly 5 Years On 50%+ Premium Buyout Offer From Vista — TTD Edges Higher

Vista Equity Partners has teamed up with Quinti Capital to submit a bid for Criteo SA in recent days, according to a Bloomberg report.


Novo Nordisk To Launch Ozempic Pills Following Flat Growth In Diabetes Segment In 2025

The Ozempic pill will be launched in Q2 2026 and be available in doses 1.5 mg, 4 mg, and 9 mg.


Novo Nordisk Shares Tumble On 2025 Earnings Miss, Weak Sales Forecast And Competition Concerns

The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%.


Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic

Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration.


Ryanair Turns Up Heat After Calling Press Briefing On Musk, Launches ‘Great Idiots Seat Sale’ Taking Aim At SpaceX Owner 

The airline’s official X account said that Ryanair CEO, Michael O’Leary will “address/undress Elon Musk’s Twitter tantrum” at a press conference on Jan. 21.


NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune Disorder Treatment

Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval.


Galapagos Stock Rises After Hours On Starting To Wind Down Cell Therapy Activities, Subsequent Workforce Reduction 

The company had announced its intent to wind down the activities after a strategic review and sale process in October.


Ryanair Pulls Plug On Prime Membership Offering After Trial Proves Too Costly 

Chief Marketing Officer Dara Brady said that to date, Ryanair has signed up over 55,000 prime members, generating over €4.4 million in subscription fees.


Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study

The trial was investigating the efficacy, safety, and pharmacokinetics of once-weekly subcutaneous amycretin and once-daily oral amycretin compared to placebo in 448 people with type 2 diabetes. 

Trust For Professional Managers - ActivePassive International Equity ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Telix already has two FDA-approved prostate cancer scan drugs: Illuccix, cleared in December 2021, and Gozellix, approved in March 2025.</li><li>Telix has not baked any Pixclara sales into its 2026 forecast, so approval would be extra to current guidance.</li><li>The FDA refused to approve Pixclara in 2025 and sought more evidence.</li></ul><p>NASDAQ-listed shares of Telix Pharmaceuticals (TLX) climbed this week as investors focused on a U.S. Food and Drug Administration (FDA) decision due next Friday on the company’s brain-cancer imaging agent.</p><p>TLX stock was trading around $11.90 on Friday, up roughly 5% from last Friday’s close of $11.29. The biggest lift this week came on Wednesday, when the shares jumped 5.5% after Telix said it had finished enrolling in a late-stage prostate imaging study.</p><h2 class="st-heading-2">Impending Decision</h2><p>The FDA’s target date for deciding on Pixclara is September 11. Pixclara is a PET scan dye meant to help doctors tell whether a glioma — an aggressive brain tumor — is coming back or whether the scan is only showing damage from earlier treatment. That distinction is difficult to make with standard imaging and can affect how patients are treated.</p><p>The product already has Fast Track and Orphan Drug status. Telix has not baked any Pixclara sales into its 2026 forecast, so approval would be in addition to its current guidance of $950 million to $970 million in revenue.</p><h2 class="st-heading-2">A Second Try At The FDA</h2><p>The company first filed for approval of Pixclara in 2024. The FDA accepted the filing and granted it priority review, then rejected it in April 2025 and requested additional supporting evidence. Telix resubmitted in March. The agency accepted the new package on April 10 and set next week’s deadline.</p><p>Telix already has two FDA-approved prostate cancer scan drugs: Illuccix, cleared in December 2021, and Gozellix, approved in March 2025. Those products now drive most sales. A kidney-cancer scan, Zircaix, was also rejected last year and is being prepared for another filing later this year.</p><p>Pixclara would give Telix a third commercial imaging product and a foothold in brain cancer. Approval would also add a product not yet included in the sales outlook, while the core prostate business continues to grow.</p><h2 class="st-heading-2">How Did TLX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around TLX stock remained ‘bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.</p><p><a href="https://stocktwits.com/symbol/TLX">TLX stock</a> has risen 59% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/bidu-stock-up-after-ai-firm-opens-hong-kong-shares-to-mainland-china-investors/cZsDXdgRJD7">BIDU Stock Up After AI Firm Opens Hong Kong Shares To Mainland China Investors</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Telix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The FDA’s target date for deciding on Pixclara is September 11.ecember 2021, and Gozellix, approved in March 2025.Telix has not baked any Pixclara sales into its 2026 forecast, so approval would be extra to current guidance.The FDA r

TLX Stock Clocks 5% Gain This Week Ahead Of FDA Decision On Brain Cancer Imaging Agent

Telix Pharmaceuticals Limited American Depositary Shares

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

APIE Trust For Professional Managers - ActivePassive International Equity ETF

Fundamentals

Latest APIE News